ASH Research Collaborative Amasses New Insights
Recently, the ASH Research Collaborative (ASH RC) took a significant step forward in the medical community by presenting promising data at a major annual gathering. This event showcased findings resulting from ongoing research into multiple myeloma and sickle cell disease, two conditions that greatly impact the lives of many individuals.
Focus on Collaborations and Real-World Evidence
During the annual meeting, one of the collaborative’s primary goals was to promote the importance of sharing data and information among researchers. Mark Crowther, MD, MSc, who chairs the ASH RC board of directors, emphasized the value of this collaboration, stating, “The ASH RC has brought the multiple myeloma and sickle cell disease communities together to generate real-world evidence.” He expressed optimism about the research being presented, highlighting its potential to lead to more discoveries in the future.
Overview of Research Variables
The organization presented six abstracts featuring insights into how collaborative data sharing improves clinical outcomes for patients. Specific topics included the development of pain management plans utilizing input from the Sickle Cell Disease Learning Community, the influence of COVID-19 on patients with multiple myeloma, and the utilization of disease-modifying therapies within the sickle cell disease patient population.
Detailed Presentation Schedule
Here are highlighted sessions you can look forward to:
Special Session: ASH Research Collaborative Data Hub Sickle Cell Disease Network - Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation on December 9 at 4:30 PM. This session aims to enrich understanding and assist in innovative care practices.
Abstract 603: Innovative Model for Creation and Use of Co-Developed Pain Management Plans for Patients with Sickle Cell Disease on December 8 at 12:30 PM. This presentation will focus on collaborative strategies in pain management.
Abstract 1972: Initial Results from the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma Study on December 7 at 5:30 PM. This study addresses critical outcomes of COVID-19 for those living with multiple myeloma.
Abstract 2312: Underutilization of Disease-Modifying Therapies in Sickle Cell Disease: A Real-World Analysis on December 7 at 5:30 PM. It reveals concerning trends regarding therapy utilization.
Abstract 2313: High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis on December 7 at 5:30 PM. This abstract discusses validation efforts for accuracy in diagnosis methods.
Abstract 3792e: Development of the ASH Research Collaborative Multiple Myeloma Program on December 8 at 6:00 PM. It focuses on generating a robust network to advance multiple myeloma research.
About the ASH Research Collaborative
The ASH Research Collaborative is dedicated to enhancing the quality of life for individuals affected by hematologic diseases through rigorous research and improved treatment methods. Their collaborations aim not only to develop innovative approaches to treatment but also to ensure that evidence-based decisions are informing care practices. Their continued efforts promise to bring forth significant advancements in the understanding and management of blood diseases.
Frequently Asked Questions
What is the ASH Research Collaborative?
The ASH Research Collaborative is a non-profit organization focused on enhancing research and treatment for blood disease patients.
What diseases does the ASH RC focus on?
The ASH RC primarily focuses on multiple myeloma and sickle cell disease.
When and where was the recent research presented?
The research was presented at a recent annual meeting, bringing together experts and stakeholders in the field.
How does the ASH RC contribute to patient care?
The ASH RC aims to improve patient care through collaborative research and by generating real-world evidence that informs treatment practices.
What can we expect from future research efforts?
Future research efforts are expected to continue focusing on innovative approaches and collaborative models to enhance outcomes for those with blood diseases.
